Pharmaceutical Product Monograph: Cefixime 400 mg Capsules
In the pharmaceutical industry, Cefixime is a potent, third-generation Oral Cephalosporin. As a pharmacist and manufacturer, I classify this molecule as a “Resistant-Strain Specialist”—it is technically designed with high stability against Beta-lactamase enzymes, allowing it to kill bacteria that have developed resistance to older penicillins and first-generation cephalosporins.
At your WHO-GMP facility in Mumbai, Cefixime 400 mg is a high-demand “Blockbuster” SKU. It is a cornerstone of outpatient infectious disease management, especially in markets where antibiotic resistance is a growing concern.
Therapeutic Profile: Primary Indications
Cefixime 400 mg is indicated for acute bacterial infections caused by susceptible Gram-positive and Gram-negative organisms.
| Indication | Clinical Context | Technical Rationale |
| Gonorrhea | STIs / Urology | Uncomplicated Gonorrhea: 400 mg is the standard single-dose treatment for Neisseria gonorrhoeae. |
| Urinary Tract (UTI) | Cystitis / Pyelonephritis | Highly effective against E. coli and Proteus mirabilis in the renal system. |
| Typhoid Fever | Gastroenterology | Frequently used as an oral alternative for multi-drug resistant (MDR) Enteric Fever. |
| Respiratory Tract | Bronchitis / Pneumonia | Targets Streptococcus pneumoniae and Haemophilus influenzae. |
| Otitis Media | ENT (Ear Infection) | High tissue penetration into the middle ear fluid. |
Mechanism: Cell Wall Synthesis Interruption
Cefixime works by sabotaging the structural integrity of the bacterial cell:
PBP Binding: The molecule binds to specific Penicillin-Binding Proteins (PBPs) located on the bacterial cell wall.
Transpeptidation Inhibition: It stops the final step of Peptidoglycan synthesis, preventing the bacteria from “knitting” its cell wall together.
Osmotic Lysis: Without a stable wall, internal pressure causes the bacterial cell to burst and die (Bactericidal action).
Beta-Lactamase Resistance: Its technical structure (specifically the R1 and R2 side chains) allows it to resist destruction by many enzymes that normally deactivate other antibiotics.
The Pharmacist’s “Technical Warning”
The “Single Dose” Rule: For Uncomplicated Gonorrhea, a single 400 mg dose is often sufficient. For other infections, it is typically taken once daily for 7–14 days.
Bioavailability: Technically, the oral suspension results in slightly higher peak blood levels than the capsule/tablet. However, the 400 mg capsule is the B2B standard for adult compliance.
Cross-Reactivity: Use with extreme caution in patients with a history of Penicillin Allergy. There is a roughly 5–10% technical risk of cross-sensitivity.
GI Side Effects: Diarrhea is the most common side effect. If it becomes severe or bloody, it may indicate C. difficile colitis.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at Healthy Life Pharma / Healthy Inc:
The “Stability” USP: Cefixime Trihydrate is sensitive to moisture. On your digital marketplace, highlight your Alu-Alu Blistering. This is a technical necessity for export to “Zone IVb” (tropical) regions to prevent the drug from degrading or losing its dissolution profile.
The “Typhoid Market”: In Southeast Asia and Africa, MDR Typhoid is a major concern. Position your Cefixime 400 mg as a “High-Potency Enteric Solution” for hospital tenders.
The “Combination” Potential: To increase your market share, consider manufacturing Cefixime + Ofloxacin or Cefixime + Clavulanic Acid FDCs. These are high-value “Super-Broad Spectrum” products popular in the Indian and export markets.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Cefixime 400 mg to support your registration in international B2B markets.